MedTrace Logo

Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria

NCT02576041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-04-18

Study results available
· View outcomes & findings →

Summary

The aim of the study is to evaluate the effects of Bilastine on patients' attention and reactivity levels by measuring psychophysical performance at a F1-high speed simulator driving test.

Conditions

  • Allergic Rhinitis
  • Urticaria

Interventions

DRUG

Bilastine

Bilastine tablets once a day for 7+3 days

DRUG

Placebo

Placebo tablets once a day during 7+3 days run in period

Sponsors & Collaborators

  • Menarini International Operations Luxembourg SA

    lead INDUSTRY

Principal Investigators

  • Patrizia Pepe · Allergology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576041 on ClinicalTrials.gov